Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Summary

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.

Timeline

Start

2021-03-01

Primary completion

2024-06-19

Completion

2024-08-06

Drugs

Indications